紀要論文

TRIPS協定後のインド製薬企業の経営戦略 : Zydus Cadilaの事例研究を中心に

The Business Strategy of the Indian Pharmaceutical Firm in the Post-TRIPS Period : A Case Study of Zydus Cadila

jpn

00229741

https://doi.org/10.15002/00014928

法政大学経済学部学会

85

4

247

285

2018-03-23

Version of Record

With the World Trade Organization’s Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS Agreement), the pharmaceutical industry became globalized. The pharmaceutical Global Value Chain (GVC) has been re-structured and has now expanded to emerging countries like India. India’s pharmaceutical industry now faces new challenges on account of this agreement. It was assumed that the introduction of pharmaceutical product patents would have a negative impact on the Indian pharmaceutical industry by hampering its growth. However, contrary to expectations, the Indian pharmaceutical industry has been growing in the post-TRIPS period. Why? Indian pharmaceutical firms have been participating in the pharmaceutical GVC through international strategic alliances with multi-national pharmaceutical companies in this post-TRIPS period. GVC participation is conducive to technological upgrading and technology transfers. The Indian pharmaceutical firms are achieving upgrading in GVC through learning and adopting state of the art technologies. This paper seeks to explore the relationship between this upgrading and a firm’s development through a case study of Zydus Cadila, India’s 4th largest pharmaceutical company. The company has achieved rapid growth and technological innovation by utilizing numerous alliances with other firms.

Article

AN00071028